Efficacy (and safety) of vaccination against SARS-CoV-2 in cancer patients on active treatment
Since the COVID-19 pandemic, cancer patients have been recognized as a group with an increased risk of complications, if they become infected with the SARS-CoV-2 virus. However, they were not included in registrational trials for COVID-19 vaccines. In the last few months data from studies investiga...
Guardado en:
Autores principales: | Tina Zupančič, Cvetka Kuhar Grašič |
---|---|
Formato: | article |
Lenguaje: | SL |
Publicado: |
Institute of Oncology Ljubljana
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/88e12c42dff240bfa773b79412dac2c8 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
What Happens to the Immune System after Vaccination or Recovery from COVID-19?
por: Bruna T. Tiyo, et al.
Publicado: (2021) -
SARS-CoV-2 immunity and an overview of the COVID-19 vaccines
por: Marković Miloš
Publicado: (2021) -
Insights Into the Immune Response of the Black Soldier Fly Larvae to Bacteria
por: Daniele Bruno, et al.
Publicado: (2021) -
Cellular Responses in the Respiratory Tract Following Intranasal administration of Peste des petits Ruminant Vaccine in Goats
por: Ezeasor,C. V, et al.
Publicado: (2013) -
REACTOGENITY OF TICK-BORNE ENCEPHALITIS VACCINE ENCEPUR ADULT AND IMMUNE RESPONSE
por: G. N. Leonova, et al.
Publicado: (2014)